“As the first therapy with a novel mechanism of action to be approved for CIDP patients in more than 30 years, this approval is an extremely important step towards addressing the unmet needs of patients with this debilitating condition and further signals argenx’s commitment to bring innovative therapeutic options to Australian patients,” said Kathryn Evans, Australia General Manager for argenx. …
New treatment milestone offers fresh hope for Australians living with CIDP
March 30, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
GBMA White Paper calls for reforms to strengthen supply chain resilience
August 10, 2026 - - Latest News -
France the first to provide comprehensive reimbursement for GLP-1s for weight loss while Australia looks on
August 10, 2026 - -
New Zealand's ACT announces plan for pharmacies to do a lot more, but also ownership and location reform
August 10, 2026 - -
Achieving value is meaningless if it undermines access to medicines
August 10, 2026 - -
Australia’s 'Biggest Week in Biotech' brings global life sciences leaders to the Gold Coast
August 9, 2026 - - Australian Biotech -
The 'Dispatched' Podcast - Week in review
August 7, 2026 - - Podcast -
A new generation is rewriting their lives living with Cystic Fibrosis
August 7, 2026 - - Latest News